Rates of Metformin Use in Stage 3b Chronic Kidney Disease Rose After FDA Label Change

Alex Y. Huang, Xian Wu, Jeremy Orloff, Jea Young Min, James FloryJournal of General Internal Medicine 2021 · DOI

Abstract

In 2016, the US Food and Drug Administration (FDA) updated the labeling for metformin, expanding its use to patients with moderate chronic kidney disease (CKD). This study analyzed National Health and Nutrition Examination Survey (NHANES) data from 2011 to 2018 to evaluate the impact of this regulatory change. We found that metformin utilization among patients with Stage 3b CKD (eGFR 30–44 mL/min/1.73 m²) more than doubled, rising from 18% to 42%. While the policy successfully increased access to first-line therapy, a non-significant increase in use among patients with severe CKD (eGFR < 30) highlights the need for continued safety surveillance.

Introduction

Metformin is widely considered the global "gold standard" for the initial treatment of Type 2 diabetes. Despite its efficacy, the drug carried a strict contraindication for decades for patients with even mildly elevated creatinine levels, primarily due to concerns regarding lactic acidosis—a rare but potentially fatal metabolic complication. However, clinical evidence increasingly suggested that metformin could be safely administered to patients with mild-to-moderate Chronic Kidney Disease (CKD).

Responding to this evidence, the FDA officially revised the metformin label in April 2016. The update replaced raw creatinine thresholds with estimated glomerular filtration rate (eGFR) guidelines, allowing clinicians to initiate metformin in patients with an eGFR $\ge$ 45 and continue treatment down to an eGFR of 30. This study investigates whether this regulatory shift translated into measurable changes in clinical practice across the United States.

Methods

The researchers conducted a retrospective analysis using data from four consecutive cycles of the National Health and Nutrition Examination Survey (NHANES), covering the period from 2011 to 2018. NHANES is a comprehensive program designed to assess the health and nutritional status of the US population through a combination of interviews and physical examinations.

The study population consisted of adults with diabetes, identified through self-reporting or an HbA1c level $\ge$ 6.5%. Participants were stratified into four categories based on kidney function:

  • eGFR $\ge$ 60: Normal or mildly decreased function.
  • eGFR 45–59: Stage 3a CKD.
  • eGFR 30–44: Stage 3b CKD.
  • eGFR < 30: Stage 4/5 CKD (metformin remains contraindicated).

Statistical analysis was performed using the R "survey" package to apply population weights, ensuring the results were representative of the broader US population.

Results

The most significant shift in clinical practice occurred among patients with Stage 3b CKD (eGFR 30–44). In this group, the proportion of patients using metformin rose from 18% in the 2011–2012 cycle to 42% by 2017–2018 ($P = 0.02$). Among patients who were not using insulin, metformin use in the Stage 3b group jumped from 34% to 62% ($P = 0.04$).

Metformin use proportions across NHANES cycles stratified by kidney function (eGFR).

In contrast, metformin use in the Stage 3a group (eGFR 45–59) remained high and stable throughout the study period. This suggests that many healthcare providers were already comfortable prescribing metformin to patients with mild-to-moderate kidney impairment even before the official FDA label change.

Characteristics of NHANES participants with diabetes and trends in medication use (2011–2018).

Beyond metformin, the study observed significant increases in the use of newer classes of diabetes medications. Specifically, the use of SGLT2 inhibitors ($P < 0.001$) and GLP1 receptor agonists ($P = 0.02$) rose significantly over the study period, reflecting broader changes in the diabetes treatment landscape.

Discussion

The findings suggest that the 2016 FDA label change acted as a critical catalyst, providing the necessary professional and legal framework for clinicians to expand metformin use to patients with Stage 3b CKD. This shift represents a successful alignment of regulatory policy with emerging clinical evidence.

However, the study also noted a numerical increase in metformin use among patients with an eGFR < 30, rising from 3.6% to 8.8%. While this trend was not statistically significant, it raises concerns about the potential over-extension of the new guidelines into populations where the drug remains contraindicated.

Limitations and Future Directions

The study's reliance on NHANES data presents certain limitations. The two-year aggregation of data cycles makes it difficult to pinpoint the exact timing of the trend relative to the April 2016 announcement. Furthermore, the data does not allow for a distinction between drug initiation and continuation, which have different eGFR thresholds under the new guidelines. Future research utilizing large-scale electronic health record (EHR) datasets is essential to monitor safety outcomes, such as the incidence of lactic acidosis, in the Stage 3b and Stage 4 populations as utilization continues to evolve.

Summary updated

BibTeX
@article{huang2021rates,
  author = {Alex Y. Huang and Xian Wu and Jeremy Orloff and Jea Young Min and James Flory},
  title = {{Rates of Metformin Use in Stage 3b Chronic Kidney Disease Rose After FDA Label Change}},
  journal = {Journal of General Internal Medicine},
  year = {2021},
  doi = {10.1007/s11606-020-06380-2},
}
Figure